During their Q4 earnings call, CEO Brian Lian reaffirmed Viking's intention to launch VK2735 as an auto-injector. We do plan to introduce an auto-injector in the Phase 3 program. So we would ...

Viking Therapeutics (VKTX), the developer of ... anticipate will be significant commercial demand,” said Viking CEO Brian Lian in a press release. Despite the news, Viking’s stock fell over ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

These capacities are expandable at Viking's discretion. "We are excited to enter into this agreement with one of the world’s leading CDMOs in the peptide space," said Brian Lian, Ph.D., chief ...

“CordenPharma's established presence in commercial peptide manufacturing gives us confidence in their ability to deliver supply commensurate with what we anticipate will be significant commercial ...

According to Viking, the collaboration will leverage CordenPharma’s expertise in peptide drug substance, sterile injectables, and oral solid dosage manufacturing to facilitate scalability and supply ...

Brian Lian, Ph.D., CEO of Viking Therapeutics, expressed confidence in CordenPharma’s ability to meet the anticipated significant commercial demand for VK2735 due to their established presence ...

The deal includes injectable and oral formulations of the medicine, both of which are being tested in clinical trials right now. The companies have long worked together, according to Viking CEO Brian ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and other drugs, the CDMO’s investment plan is paying off big time.

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...